Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia

Background: Therapy for acute lymphoblastic leukemia (ALL) are currently initially efficient, but even if a high percentage of patients have an initial complete remission (CR), most of them relapse. Recent data shows that immunotherapy with either bispecific T-cell engagers (BiTEs) of chimeric antig...

Descripción completa

Detalles Bibliográficos
Autores principales: Deak, Dalma, Pop, Cristina, Zimta, Alina-Andreea, Jurj, Ancuta, Ghiaur, Alexandra, Pasca, Sergiu, Teodorescu, Patric, Dascalescu, Angela, Antohe, Ion, Ionescu, Bogdan, Constantinescu, Catalin, Onaciu, Anca, Munteanu, Raluca, Berindan-Neagoe, Ioana, Petrushev, Bobe, Turcas, Cristina, Iluta, Sabina, Selicean, Cristina, Zdrenghea, Mihnea, Tanase, Alina, Danaila, Catalin, Colita, Anca, Colita, Andrei, Dima, Delia, Coriu, Daniel, Einsele, Hermann, Tomuleasa, Ciprian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934055/
https://www.ncbi.nlm.nih.gov/pubmed/31921126
http://dx.doi.org/10.3389/fimmu.2019.02856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934055/
https://www.ncbi.nlm.nih.gov/pubmed/31921126
http://dx.doi.org/10.3389/fimmu.2019.02856

Ejemplares similares